Corporate/M&A: International

Jones Day holds a solid track record in handling outbound acquisitions and global transactions involving assets in Japan. Additionally advises multinationals, investment management firms and private equity houses regarding inbound investments. Active across a range of sectors including pharmaceuticals, natural resources, insurance and technology. Leverages its global network to provide seamless advice on cross-border transactions and offers further assistance with aspects such as antitrust and labour law. Key clients include Sumitovant Biopharma, Bally's Corporation, and JERA Power International BV.

A client praises the Jones Day team's service, commercial awareness and value as "excellent on all fronts," explaining the law firm is "efficient and thorough without over-servicing."

A further client states: "Jones Day is one of the top international law firms and very reliable. They're speedy, reliable and know how our corporation thinks."

Jones Day advised Sumitovant Biopharma on its USD217 million acquisition of all outstanding shares in Urovant Sciences, making Urovant a wholly owned subsidiary.

Greg Salathé is a key contact for clients.